ALK7 (ACVR1C): Molecular Characteristics and Metabolic Regulatory Functions of a Type I Receptor in the TGF-β Superfamily

Author: Senior Product Manager of UA Views：8

This article focuses on the molecular identity, structural characteristics, and biological functions of ALK7 (ACVR1C), systematically elaborating its gene localization and protein domain composition as a type I receptor of the TGF-β receptor superfamily, clarifying its essential differences from anaplastic lymphoma kinase (ALK) in molecular classification, signaling mechanisms, and disease associations, and analyzing its metabolic functional positioning in regulating adipocyte lipolysis through the Activin E-SMAD2/3 axis.

Recent Advances
Product Information

Recent Advances

ALK7 (ACVR1C): Molecular Characteristics and Metabolic Regulatory Functions of a TGF-β Superfamily Type I Receptor

Summary: This article focuses on the molecular identity, structural features, and biological functions of ALK7 (ACVR1C), systematically describing its gene localization and protein domain composition as a Type I receptor of the TGF-β receptor superfamily, clarifying its essential differences from anaplastic lymphoma kinase (ALK) in terms of molecular class, signaling mechanism, and disease association, and analyzing its metabolic functional positioning in regulating adipocyte lipolysis via the Activin E-SMAD2/3 axis.

I. Molecular Identity of ALK7: Essential Differences from ALK.

Discussing ALK7 first requires clarifying an easily confused issue: ALK7 and anaplastic lymphoma kinase (ALK) are two completely different molecules that share only the "ALK" prefix in their names. The ALK gene is located in the human chromosome 2p23.2 region, spans approximately 728 kb, and encodes a 1620-amino-acid receptor tyrosine kinase. It was named after its discovery in 1994 as an NPM-ALK fusion protein in anaplastic large cell lymphoma; its abnormally activated form is a fusion gene generated by chromosomal translocation, making it a classic TKI drug target second only to EGFR. ALK7, by contrast, is encoded by the ACVR1C gene and belongs to the Type I receptors of the TGF-β receptor superfamily; it is a serine/threonine kinase receptor whose ligand system, signaling pathway, and disease spectrum are entirely distinct from those of ALK. This distinction is a prerequisite for accurately understanding ALK7-related research literature and also determines the fundamental differences in drug development strategies between the two——ALK targeting strategies revolve around inhibiting the kinase activity of fusion proteins, whereas ALK7 intervention logic revolves around signal regulation of the ligand-receptor axis.

II. Protein Structure of ALK7 and Receptor Complex Assembly.

As a Type I receptor of the TGF-β receptor superfamily, ALK7's protein structure comprises an extracellular ligand-binding domain, a single transmembrane region, and an intracellular serine/threonine kinase domain. Unlike receptor tyrosine kinases such as ALK, ALK7 does not possess tyrosine kinase activity but instead participates as a Type I receptor in the transmembrane transmission of TGF-β family signals. Upon ligand binding, 2 Type I receptors and 2 Type II receptors assemble into a "dimer of dimers" tetrameric receptor complex, in which the Type II receptor phosphorylates and activates the GS domain of ALK7, thereby initiating downstream SMAD2/3 signaling. This receptor assembly mode determines that ALK7 activation depends on the precise spatial pairing of Type I and Type II receptors, and also explains why interventions targeting this pathway can achieve selectivity at the Type I receptor level while also producing mechanistic intersection at the Type II receptor level. In contrast to the "ligand-independent constitutive activation" mechanism of ALK fusion proteins, ALK7 activation retains dependence on ligand signals, making its regulatory logic closer to the fine-tuning of physiological signaling pathways.

III. Functional Positioning of ALK7 in the Activin E Signaling Axis.

ALK7 is a key receptor connecting liver-derived signals with adipose tissue lipolysis regulation. INHBE is primarily expressed in the liver, and its encoded βE subunit forms a dimer, Activin E, which is secreted into the circulation. Activin E activates SMAD2/3 signaling through receptor complexes on the adipocyte surface, inhibits PPARγ-related transcriptional programs, reduces adipocyte lipolytic capacity, and promotes lipid storage and adipocyte hypertrophy. In this pathway, ALK7 serves the core function of receiving circulating Activin E signals and initiating the intracellular cascade.

The classic pro-lipolytic signal in adipocytes is mediated by β-adrenergic receptors, which promote lipolysis by elevating cAMP levels, activating PKA, and phosphorylating proteins such as HSL and Perilipin, whereas the ALK7-SMAD2/3 pathway exerts a negative regulatory effect on lipolysis. Therefore, the common pharmacological goal of targeting ALK7 is to attenuate this inhibitory signal and promote fat mobilization, thereby achieving fat reduction. This "releasing inhibition rather than direct activation" logic of action stands in sharp contrast to the strategy of ALK fusion proteins being directly blocked by kinase inhibitors at their catalytic activity, and also determines that ALK7 drug development is more inclined toward upstream intervention approaches such as ligand neutralization or receptor expression silencing.

IV. Tissue Expression Characteristics of ALK7 and Targeted Delivery Considerations.

Tissue expression determines the delivery requirements of the two targeting routes. INHBE has a relatively well-defined liver expression profile, allowing hepatocyte delivery via GalNAc-conjugated siRNA; ALK7-targeting siRNA, however, needs to enter adipocytes, and adipose tissue delivery is technically more challenging. Tissue expression data support strong RNA enrichment of ALK7 in adipose tissue, providing a target-expression basis for adipocyte delivery. In terms of signal coverage, silencing INHBE reduces circulating ligand levels and theoretically can affect all tissues expressing ALK7 receptors; silencing ACVR1C reduces receptor expression locally in adipocytes, with a scope more confined to adipose tissue itself but covering ALK7 receptor signals including those from other ligands. This trade-off between delivery requirements and coverage scope is a core consideration in ALK7 targeting strategy design that distinguishes it from ALK small-molecule inhibitors.

V. Conclusion.

ALK7, as a Type I receptor of the TGF-β receptor superfamily encoded by the ACVR1C gene, has become a emerging target of great interest in the field of metabolic diseases, especially obesity treatment, by virtue of its essential differences from anaplastic lymphoma kinase in gene origin, kinase class, and activation mechanism; its molecular mechanism of assembling tetrameric complexes with Type II receptors and initiating SMAD2/3 signaling; its core functional positioning in connecting liver-derived Activin E signals with adipocyte lipolysis inhibition; and the delivery feasibility supported by adipose tissue RNA enrichment and the independent identification of ACVR1C by large-scale population genetics.

In basic research on ALK7 receptors and drug development for metabolic diseases, high-quality recombinant ALK7 protein is a core tool for dissecting its binding mechanism with Activin E ligands, evaluating receptor complex assembly, and screening targeted intervention molecules. The GST tag facilitates efficient purification via glutathione affinity chromatography and can serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. To meet the needs of ALK7 functional research and obesity therapeutic drug development, U-protein Express provides ACVR1C(ALK7) GST Tag Protein, Human. This product is suitable for applications including binding activity analysis of ALK7 with Activin E and Type II receptors, research on ALK7-mediated SMAD2/3 signaling pathway activation, in vitro evaluation of small nucleic acid drugs and receptor blockers targeting ACVR1C, and mechanistic exploration of the metabolic signaling axis in which ALK7 participates.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next